Navigation Links
Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
Date:12/9/2009

atory clinical trial will be required to establish efficacy and safety of the product for marketing authorization purposes. Helix intends to continue to make preparations to conduct a European Phase III trial for this purpose, although the timing of filing the European Phase III CTA has not yet been established. The timing of both the planned U.S. and European trials will be contingent on the timing of regulatory approvals of the trials as well as obtaining additional capital.
  • Enrollment in the ongoing Phase II clinical trial in patients with anogenital warts ("AGW") in Sweden and Germany was completed subsequent to the Company's first quarter of fiscal 2010.

    • Financing

    • Completed a private placement financing on September 8, 2009 for gross proceeds of $13,581,250.
    • Prof. Majewski, stepped down from the Board of Directors to assume the advisory role of European medical director, effective August 11, 2009.
    • Prof. Kazimierz Roszkowski-Sliz was appointed to the Board of Directors on August 17, 2009.

    FINANCIAL REVIEW

    During the first quarter of fiscal 2010, the Company recorded a loss of $3,473,000 or $0.06 per common share, resulting in a higher loss of $1,152,000 when compared to the first quarter of fiscal 2009. The Company recorded a loss of $2,321,000, or $0.05 per common share in the first quarter of fiscal 2009.

    Revenues in the first quarter of fiscal 2010 totalled $1,020,000 (2009 - $1,119,000), resulting in a decrease of $99,000 or 8.8% when compared to the first quarter of fiscal 2009.

    Product revenues totalled $903,000 in the first quarter of fiscal 2010 and represents 88.5% of total revenues. When compared to the first quarter of fiscal 2009, product revenues decreased by $18,000 or 2.0%. Sales of both Klean-Prep® and Imunovir® were marginally higher in the quarter, however these were offset by the net decrease in combined
    '/>"/>

    SOURCE Helix BioPharma Corp.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
    2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
    3. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
    4. Helix BioPharma Corp. Announces Fiscal 2009 Results
    5. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
    6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    7. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    9. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
    10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
    11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/17/2013)... , June 17, 2013 Velplex, LLC announced ... a technology platform that connects buyers and sellers of ... an industry leader. Why? It,s because ... are intimately familiar with the dental industry. They have ... and have diligently worked to negotiate some of the ...
    (Date:6/17/2013)... DNAtrix Inc., experts in oncolytic virus development, ... on the company,s lead product, DNX-2401, at the Replicating ... Canada on June 18, 2013. ... leader in the field of oncolytic virus therapy, will ... I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY ...
    (Date:6/17/2013)... ST. PAUL, Minn. , June 17, 2013 ... and branding and design agency, Larsen, was awarded the Silver ... Purpose, Repositioning Prime Therapeutics." The award was presented at the ... Awards Ceremony held June 13 at the AXA ... The Silver Anvil, which has been presented ...
    Breaking Medicine Technology:TopProdeals.com Rises to Top as Discount Dental Supply Leader 2DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus 2Prime Therapeutics receives prestigious Silver Anvil Award from Public Relations Society of America 2
    ... March 23 Magellan Biosciences, Inc., an emerging ... has become the first to offer minocycline and telavancin ... and Drug Administration (FDA) has cleared TREK-brand Sensititre MIC ... negative bacterial isolates, as well as telavancin against Gram ...
    ... and MORRISTOWN, N.J. , March 23 MicroMass Communications, Inc., a world leader in behavioral marketing, ... be supporting the launch of the new center and its mission of promoting the growth of North Carolina ,s ... ... , , ...
    Cached Medicine Technology:FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 2FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 3FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni 4MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 2MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 3MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 4
    (Date:6/18/2013)... St. Petersburg, FL (PRWEB) June 19, 2013 ... only 5 minutes a day could boost your health ... says Kathy Heshelow, founder of Sublime Beauty®. "It is ... been practiced for centuries but became a lost art. ... and celebrities know about Skin Brushing, and so do ...
    (Date:6/18/2013)... PA, June 19, 2013 Recent studies linking ... of bullying-related suicide among young people, led the ... assemble an expert panel to focus on these ... the complex relationship between youth involvement in bullying ... among youth is a significant public health problem, ...
    (Date:6/18/2013)... York (PRWEB) June 19, 2013 Parker ... the rights of victims injured by dangerous drugs and ... an Arizona woman who alleges that she was ... filed on May 30th in the U.S. District Court ... No. 2:13-cv-12677) in the multidistrict litigation entitled In Re: ...
    (Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
    (Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
    Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Bullying and suicide among youth is a public health problem 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 2Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 3Health News:Boston Scientific and American Medical Systems Named in Transvaginal Mesh Lawsuit Filed by Parker Waichman LLP on Behalf of Arizona Woman 4Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2
    ... study has broken the hopes that a combination of ... alternative for preventing strokes //in people with the abnormal ... therapy, of warfarin. ,Canadian researchers have cut ... there is a higher incidence of not only of ...
    ... Haryana Health Minister Kartar Devi today said government had increased ... education by 50 per cent this fiscal to implement various ... a five-day yoga training camp, being conducted by Swami Ramdev ... necessary to popularise yoga in view of our rich cultural ...
    ... progressive degeneration of the nerves across the body. Some ... and Kennedy disease. // Researchers have found that ... of the transport of proteins within cells. Hence they ... is unraveled then these diseases could be easily treated. ...
    ... A 26-year-old woman has delivered identical quadruplets, a rarity ... globally, at a corporate hospital here. // ... girl babies- Aditi, Aakriti, Akshathi, Aapthi, at the Apollo ... her full term, without any medical complications, doctors said., ...
    ... Pharma major Ranbaxy Laboratories Ltd has entered into a ... Zonisamide Capsules // , which are used for the ... the agreement products would be developed and submitted for ... the products under the the company's label. , ...
    ... detected here today even as health officials collected blood ... the disease. // ,Officials said a team ... including two children were suffering from jaundice., ,The ... the area as doctors collected blood samples of 20 ...
    Cached Medicine News:Health News:Studies Show Combination Drugs As A Poor Substitute For Anti-Coagulants In Stroke 2Health News:Transport of Proteins Unravels the Mystery behind Neurodegenerative Diseases 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: